PMID- 21933581
OWN - NLM
STAT- MEDLINE
DCOM- 20120427
LR  - 20181201
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 124
IP  - 16
DP  - 2011 Aug
TI  - Matrix metalloproteinase-9 was involved in the immuno-modulatory defect of 
      mesenchymal stem cell from chronic myeloid leukemia patients.
PG  - 2423-30
AB  - BACKGROUND: Overwhelming evidences on chronic myeloid leukemia (CML) indicate 
      that patients harbor quiescent CML stem cells that are responsible for blast 
      crisis. While the hematopoietic stem cell (HSC) origin of CML was first suggested 
      over 30 years ago, recently CML-initiating cells beyond HSCs are also being 
      investigated. METHODS: We have previously isolated fetal liver kinase-1-positive 
      (Flk1(+)) cells carrying the BCR/ABL fusion gene from the bone marrow of Ph(+) 
      patients with hemangioblast property. In this study, we isolated CML 
      patient-derived Flk1(+)CD31(-)CD34(-) mesenchymal stem cells (MSCs) and detected 
      their biological characteristics and immunological regulation using fluorescence 
      in situ hybridization (FISH) analysis, fluorescence activated cell sorting 
      (FACS), enzyme-linked immunoadsorbent assay, mixed lymphocyte reaction assays; 
      then we compared these characters with those of the healthy donors. RESULTS: CML 
      patient-derived Flk1(+)CD31(-)CD34(-) MSCs had normal morphology, phenotype and 
      karyotype while appeared impaired in immuno-modulatory function. The capacity of 
      patient Flk1(+)CD31(-)CD34(-) MSCs to inhibit T lymphocyte activation and 
      proliferation was impaired in vitro. CONCLUSIONS: CML patient-derived MSCs have 
      impaired immuno-modulatory functions, suggesting that the dysregulation of 
      hematopoiesis and immune response may originate from MSCs rather than 
      hematopoietic stem cells (HSCs). MSCs might be a potential target for developing 
      efficacious treatment for CML.
FAU - Zhu, Xi-Shan
AU  - Zhu XS
AD  - Institute of Internal Oncology, Center of Tumor Research and Therapy, Beijing 
      Shijitan Hospital, Capital Medical University (the Ninth Medical College of 
      Peking University), Beijing 100038, China. mountain.red@163.com
FAU - Shi, Wei
AU  - Shi W
FAU - An, Guang-Yu
AU  - An GY
FAU - Zhang, Hong-Mei
AU  - Zhang HM
FAU - Song, Yu-Guang
AU  - Song YG
FAU - Li, You-Bin
AU  - Li YB
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Antigens, CD34)
RN  - 0 (Platelet Endothelial Cell Adhesion Molecule-1)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antigens, CD34/genetics/metabolism
MH  - Apoptosis/drug effects
MH  - Blotting, Western
MH  - Cell Cycle/drug effects
MH  - Cells, Cultured
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Flow Cytometry
MH  - Fusion Proteins, bcr-abl/genetics/metabolism
MH  - Humans
MH  - Immunomodulation
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotype
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL 
      Positive/*enzymology/*immunology/metabolism
MH  - Male
MH  - Matrix Metalloproteinase 9/genetics/*metabolism
MH  - Mesenchymal Stem Cells/cytology/*immunology
MH  - Middle Aged
MH  - Platelet Endothelial Cell Adhesion Molecule-1/genetics/metabolism
MH  - T-Lymphocytes
MH  - Vascular Endothelial Growth Factor Receptor-2/genetics/metabolism
MH  - Young Adult
EDAT- 2011/09/22 06:00
MHDA- 2012/04/28 06:00
CRDT- 2011/09/22 06:00
PHST- 2011/09/22 06:00 [entrez]
PHST- 2011/09/22 06:00 [pubmed]
PHST- 2012/04/28 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2011 Aug;124(16):2423-30.